María Collado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
María Collado has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Juan Carlos Hernández-Boluda
Department of Hematology, Hospital Clínico Universitario, Valencia, Spain
2 shared publications Alberto Alvarez-Larrán
Hematology Department, Hospital del Mar, IMIM, Barcelona, Spain
1 shared publication- Alberto Alvarez-Larrán
Hematology Department. Hospital Clínic, Barcelona, Spain
1 shared publication - Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
1 shared publication Carlos Solano
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
1 shared publicationEduardo Tormo
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
1 shared publication
Latest Publications
- 1 November 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1278-1284
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia
- 1 November 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1278-1284
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia
- Open Access
- 23 June 2010
- Published by Wiley in American Journal of Hematology
- Vol. 85 (7) , 482-486
XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia
Chronic myeloid leukemia (CML) is driven by the BCR‐ABL protein, which promotes the proliferation and viability of the leukemic cells. Moreover, BCR‐ABL induces genomic instability that can contribute to the emergence of resistant clones to the ABL kinase inhibitors. It is currently unknown whether the inherited individual capability to repair DNA damage could affect the treatment results. To address this, a comprehensive analysis of single nucleotide polimorfisms (SNPs) on the nucleotide excision repair (NER) genes (ERCC2‐ERCC8, RPA1‐RPA3, LIG1, RAD23B, XPA, XPC) was performed in 92 chronic phase CML patients treated with imatinib upfront. ERCC5 and XPC SNPs correlated with the response to imatinib. Haplotype analysis of XPC showed that the wild‐type haplotype (499C‐939A) was associated with a better response to imatinib. Moreover, the 5‐year failure free survival for CA carriers was significantly better than that of the non‐CA carriers (98% vs. 73%; P = 0.02). In the multivariate logistic model with genetic data and clinical covariates, the hemoglobin (Hb) level and the XPC haplotype were independently associated with the treatment response, with patients having a Hb ≤11 g/dl (Odds ratio [OR] = 5.0, 95% confidence interval [CI] = 1.5–16.1) or a non‐CA XPC haplotype (OR = 4.1, 95% CI = 1.6–10.6) being at higher risk of suboptimal response/treatment failure. Our findings suggest that genetic polymorphisms in the NER pathway may influence the results to imatinib treatment in CML. Am. J. Hematol., 2010.
- 23 June 2010
- Published by Wiley in American Journal of Hematology
- Vol. 85 (7) , 482-486
Open AccessXPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia
Chronic myeloid leukemia (CML) is driven by the BCR‐ABL protein, which promotes the proliferation and viability of the leukemic cells. Moreover, BCR‐ABL induces genomic instability that can contribute to the emergence of resistant clones to the ABL kinase inhibitors. It is currently unknown whether the inherited individual capability to repair DNA damage could affect the treatment results. To address this, a comprehensive analysis of single nucleotide polimorfisms (SNPs) on the nucleotide excision repair (NER) genes (ERCC2‐ERCC8, RPA1‐RPA3, LIG1, RAD23B, XPA, XPC) was performed in 92 chronic phase CML patients treated with imatinib upfront. ERCC5 and XPC SNPs correlated with the response to imatinib. Haplotype analysis of XPC showed that the wild‐type haplotype (499C‐939A) was associated with a better response to imatinib. Moreover, the 5‐year failure free survival for CA carriers was significantly better than that of the non‐CA carriers (98% vs. 73%; P = 0.02). In the multivariate logistic model with genetic data and clinical covariates, the hemoglobin (Hb) level and the XPC haplotype were independently associated with the treatment response, with patients having a Hb ≤11 g/dl (Odds ratio [OR] = 5.0, 95% confidence interval [CI] = 1.5–16.1) or a non‐CA XPC haplotype (OR = 4.1, 95% CI = 1.6–10.6) being at higher risk of suboptimal response/treatment failure. Our findings suggest that genetic polymorphisms in the NER pathway may influence the results to imatinib treatment in CML. Am. J. Hematol., 2010.